GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » Tax Rate %

XTL Biopharmaceuticals (XTL Biopharmaceuticals) Tax Rate % : 0.00% (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. XTL Biopharmaceuticals's Tax Expense for the three months ended in Sep. 2023 was $0.00 Mil. XTL Biopharmaceuticals's Pre-Tax Income for the three months ended in Sep. 2023 was $-0.22 Mil. Therefore, XTL Biopharmaceuticals's Tax Rate % for the quarter that ended in Sep. 2023 was 0.00%.

XTL Biopharmaceuticals Tax Rate % Historical Data

The historical data trend for XTL Biopharmaceuticals's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Tax Rate % Chart

XTL Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

XTL Biopharmaceuticals's Tax Rate % for the fiscal year that ended in Dec. 2022 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2022 )/Pre-Tax Income (A: Dec. 2022 )
=0/-1.348
=0.00 %

XTL Biopharmaceuticals's Tax Rate % for the quarter that ended in Sep. 2023 is calculated as

Tax Rate %=Tax Expense (Q: Sep. 2023 )/Pre-Tax Income (Q: Sep. 2023 )
=0/-0.215
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Tax Rate % Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » Tax Rate %
Comparable Companies
XTAE:CANF XTAE:CBI XTAE:PPBT XTAE:MTLF XTAE:BOLT XTAE:PLNT XTAE:DNA XTAE:HDST-M XTAE:GFC-M XTAE:EVGN OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
XTLB:Israel H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989